From The Motley Fool · Prosper Junior Bakiny · · 1m
Novo Nordisk Shares Jump After Strong Q3 Results
Novo Nordisk's stock surged 6% post-earnings as oral Wegovy drives recovery.
In brief
Novo Nordisk's stock surged 6% post-earnings as oral Wegovy drives recovery. Novo Nordisk raised 2026 fiscal year guidance after strong Q3 results with oral Wegovy generating $810 million revenue. Originally reported by The Motley Fool.
Novo Nordisk Q3 Results
Novo Nordisk reported strong third-quarter results with oral Wegovy generating 5.4 billion dkk revenue.
“The company launched this weight loss pill, the first of its kind to earn approval, in January”
Oral Wegovy Performance
Oral Wegovy has surpassed three million prescriptions with 80% of patients new to GLP-1 treatments.
“as of June, oral wegovy had surpassed three million prescriptions, and more than 80% were for patients who had never taken glp-1s before”
Q3 Financials
Novo's net sales rose 6% year over year to 79.2 billion dkk despite 16% net income drop.
“Novo reported that, as of June, oral wegovy had surpassed three million prescriptions”
Guidance Update
Novo raised 2026 fiscal year guidance with revenue expected flat year over year versus previous 3% drop forecast.
“It now expects revenue to be flat (at the midpoint) year over year, while the previous guidance implied a 3% year-over-year drop at the midpoint”
Oral Wegovy Catalysts
Oral Wegovy approved in Germany and U.K. with potential label expansion for metabolic dysfunction.
“Novo has submitted an application to the u.s. food and drug administration for oral wegovy as a potential treatment for metabolic dysfunction-associated steatohepatitis”
CagriSema Development
CagriSema shows promise in weight loss and diabetes with potential to steal market share from Eli Lilly.
“CagriSema also posted strong clinical trial results in diabetes”
Pipeline Candidates
Zenagamtide in subcutaneous and oral formulations for diabetes and weight loss.
“The company's phase 3 pipeline features zenagamtide, a promising diabetes and weight-loss medicine”
The one thing
Novo Nordisk raised 2026 fiscal year guidance after strong Q3 results with oral Wegovy generating $810 million revenue.
